New target discovery I&I | Ep. 953

3.8.2026

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we’re diving into the economics of gene therapy—the risks, rewards, and what needs to happen for this model to survive. We’ll break down the shift from lifelong treatments to single-shot cures, the financial math behind it, and the challenges of scaling to common diseases. If you’re in biotech or investing in it, you’ll want to understand where this is headed. Let’s get into it.

We are now publishing 7x per week according to the following cadence:

• Mondays: Stocks

• Tuesdays: Biotech

• Wednesdays: Podcast

• Thursdays: Markets

• Fridays: News

• Saturdays: Podcast

• Sundays: Strategy

We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.

SUBSCRIBE TO PODCAST HERE:

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Enough shilling for the day, lots to cover this week, let's get started!

Immunoproteomics Upstages Genomics in Inflammation and Immunology Target Discovery

Inflammation and immunology (I&I) are poised on the brink of a target discovery revolution that promises to transform not only their own fields but also have profound ripple effects across a multitude of other disease areas. Central to this transformation is the ascendancy of proteomics—specifically immunoproteomics—over traditional genomics as the primary driver for uncovering therapeutic targets. This shift marks a significant evolution in how researchers approach the complex landscape of immune and inflammatory diseases, offering more precise and actionable insights into disease mechanisms and potential interventions.